Abstract
BackgroundIntravenous adenosine is the recommended treatment for paroxysmal supraventricular tachycardia (PSVT). There is no official recommended method of giving adenosine. We compared the success rates between a standard and alternative method of first dose intravenous adenosine in PSVT.MethodsA pilot parallel randomized controlled study was conducted in the emergency department of a tertiary care hospital. Eligible patients were stable PSVT adult patients. We used block randomization and divided them into two groups, the standard method (double syringe technique of 6 mg of adenosine), and the alternative method (similar to the standard method, then immediately followed by elevating the arm to 90° perpendicular to a horizontal plane for 10 s). The primary outcome was the success rate of electrocardiogram (ECG) response which demonstrated termination of PSVT (at least two-fold of the RR-interval widening or sinus rhythm conversion). Secondary outcomes were complications within one minute after the injection.ResultsWe allocated 15 patients in each group and analyzed them as intention-to-treat. The success rate was 86.7% in the alternative group and 80% in the standard group (risk difference 6.7%, 95% confidence interval − 19.9 to 33.2%, P 1.00). Complications within one minute after adenosine injection were also similar in both groups, 14 of 15 patients (93%) in each group had no complications, without significant difference.ConclusionsNo evidence of the difference between alternative and standard methods occurred, in terms of the success rate of ECG response and complications within one minute after adenosine injection. The standard method of adenosine injection is a safe, easy-to-administer, and widely available treatment for PSVT.Trial Registration: TCTR20200609001.
Highlights
Supraventricular tachycardia (SVT) is a common cardiac problem, which can be a life-threatening condition requiring immediate treatment, in the emergency department (ED)
The standard recommended treatment of acute hemodynamically stable SVT supported by the 2020 American Heart Association update on Advanced Cardiovascular Life Support (ACLS) is adenosine intravenous double syringe technique via a T connector
Characteristics of study subjects A total of 30 patients were eligible to enroll and randomized, 15 patients were allocated in each group
Summary
Supraventricular tachycardia (SVT) is a common cardiac problem, which can be a life-threatening condition requiring immediate treatment, in the emergency department (ED). Paroxysmal supraventricular tachycardia (PSVT) is an abnormal fast cardiac rhythm, originated above the bundle of His, mostly atrioventricular (AV) node. Due to its fast metabolization (approximate half-life is about 2–5 s), a fast intravenous injection is required for the best treatment outcome. The standard recommended treatment of acute hemodynamically stable SVT supported by the 2020 American Heart Association update on Advanced Cardiovascular Life Support (ACLS) is adenosine intravenous double syringe technique via a T connector. Intravenous adenosine is the recommended treatment for paroxysmal supraventricular tachycardia (PSVT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.